

Serum Insulin And Lipid Profile In Normal And Preeclamptic Pregnant Women

Thesis

**Submitted for Partial Fulfillment of
Master Degree in Obstetrics & Gynaecology
By**

Ahmed Sobhi Mohamed

M.B.B.Ch.

Supervisors

Prof. Dr. Alaa El-Din Abd El-Aziz El-Guindy

**Professor of Obstetrics & Gynaecology
Faculty Of Medicine
Ain Shams University**

Dr. Mohamed Ahmed El-Kadi

**Lecturer of Obstetrics & Gynaecology
Faculty Of Medicine
Ain Shams University**

**Faculty Of Medicine
Ain Shams University**

2006

Acknowledgement

I wish to express my deepest gratitude and respect for all my supervisors for their fine encouragement, guidance and help.

I am deeply grateful to ***prof. Dr. Alaa El Din Abd El-Aziz El-Guindy*** Professor of Obstetric and Gynecology, Ain Shams University, for the great support and encouragement he gave me throughout the whole study. It is an honor to work under his guidance and supervision.

Also, my deepest gratitude to ***Dr. Mohamed Ahmed El-Kadi*** Lecturer of Obstetric and Gynecology, Ain Shams University for his close supervision and continuous help throughout the study.

My deepest gratitude to my family and friends, for their support especially my brother who helped me in typing and arrangement of this work.

Last but not least, I have to thank the kind patients who participated in this work and without whom neither this nor other works could be accomplished.

I would like to dedicate this work to my great wife ***Riham*** who gave me all types of support.

Introduction:

Preeclampsia, a multisystem disorder unique to human pregnancy, remains a leading cause of maternal and fetal morbidity and mortality, particularly in developing countries. Prevalence for the condition has been variously cited as occurring in a range of 2% to 10% of pregnancies. Most recently, the incidence rate is 1.3% to 6.7% in developing countries and 0.4% to 2.8% in industrialized countries. (*Villar et al., 2004*)

Many researchers consider preeclampsia an end-stage disease. Recent data also suggest that it is not one disease but a heterogeneous syndrome. The condition is marked by the sudden onset of maternal hypertension, proteinuria, edema, excessive weight gain, and increased vascular resistance. The fetus is also affected, with risk of growth restriction, intrauterine

death, and premature delivery. An abnormal interaction of maternal and fetal tissue occurs at the uteroplacental interface. Although the detailed etiology of the condition is still unknown, it has become apparent that the cytotrophoblast differentiation pathway that leads to uterine invasion is defective. (***Fisher et al., 2004***)

In the last few years, much of the researchers published have highlighted the many factors that have been found to be associated with preeclampsia. Increased insulin resistance and pregnancy dyslipidemia were important subjects for these researchers. (***Enquobahrie et al.,2004 and Thadhani R et al.,2004***).

Early dyslipidemia that occurs in women who go on to develop preeclampsia may also serve as a diagnostic marker. In some studies, at 13 weeks` gestation, women who later developed preeclampsia had significantly higher levels of LDL cholesterol, triglycerides, and LDL/HDL ratios and significantly lower HDL levels than control women. In these studies, there was a linear increase in preeclampsia risk with increasing levels of LDL cholesterol, triglyceride concentrations, and LDL/HDL ratio. **(Raijmakers MT et al., 2004).**

Hyperinsulinemia and dyslipidemia are known to be associated with essential hypertension but their role in pregnancy-induced hypertension remains unclear.

Higher fasting cholesterol and insulin levels in mid- to late pregnancy are associated with increased risk for PIH. These

observations support a role for insulin resistance in the development of this complication of pregnancy. **(Solomon et al., 1999)**

Similarities in certain biochemical variables between preeclampsia and the insulin resistance syndrome imply a possible link between insulin resistance and preeclampsia. Preeclampsia is a state of increased insulin resistance, and it persists for at least three months after pregnancy. This may be a pathogenetic factor in preeclampsia and may contribute to the excess cardiovascular morbidity among women with prior preeclampsia. **(Kaaja et al., 1999)**

Aim of the work:

The aim of the study is to measure the serum insulin, cholesterol, triglycerides, low density lipoprotein and high density lipoprotein in cases of preeclampsia compared with normal pregnant women

Patients and methods:

This study will be carried out on 90 women recruited from antenatal outpatient clinic and Obstetric Department of Ain

Shams University maternity Hospital. They will be divided into two groups:

- Group 1 (Study group) : 45 preeclamptic women.
- Group 2 (Control group) : 45 women with normal pregnancy.

***Inclusion criteria:**

A) Normal Control group:

Composed of 45 pregnant women(age from 18 – 35 years) in the third trimester selected according to the following criteria:

1. No present, past, family or obstetric history suggestive of hypertension or diabetes mellitus.
2. All cases are normotensive with B.P<140/90mmHg on two separate occasions 6 hours apart with no albuminuria.
3. No history of other medical complications during pregnancy.
4. Normal fasting blood glucose levels.

B) Preeclamptic group:

Composed of 45 preeclamptic patients(age from 18 – 35 years) in their third trimester selected according to the following criteria:

1. No present, past, family or obstetric history suggestive of chronic hypertension or diabetes mellitus.
2. All cases are diagnosed to have preeclampsia with blood pressure more than or equal to 140/90mmHg on two separate occasions and positive albuminuria with or without edema.

3. The degree of preeclampsia varies from mild (BP $\geq$ 140/90 mmHg and albumin +1 dipstick) to severe degree (BP $>$ 160/100 mmHg and albumin $\geq$ +2 dipstick).
4. No history of other medical complications during pregnancy.
5. Normal fasting blood glucose levels.

***Exclusion criteria include:**

1. Women with past history of any medical disorders such as hypertension, diabetes mellitus or renal diseases.
2. Women with other complications of pregnancy.
3. Women who received any antihypertensive medication.
4. Women with multiple pregnancy.

***The two groups will be subjected to the following:**

1. History: Detailed history from each patient with special reference to present, past, family and obstetric histories.
2. Examination:
 - Body built and weight.
 - Calculation of body mass index.
 - Chest and heart examination.
 - Checking for edema of both lower limbs.
 - Abdominal examination.
3. Investigations:
 - Blood urea and s.creatinine
 - Urine analysis to detect albumin by dipsticks.

- Venous blood glucose: fasting (for at least 8 hours).
- Serum insulin level: fasting (for at least 8 hours).
- Serum triglycerides, cholesterol, high-density lipoprotein and low density lipoprotein (fasting for 12 hours).

***Specimen collection and preparation for analysis:**

- Blood samples will be collected by venipuncture into plain tubes (without anticoagulant) avoiding hemolysis, after overnight fasting.
- Blood samples will be centrifuged after complete clotting at 4000 rpm for 10 min.
- The separated serum will be stored frozen at -20°C.

***Laboratory investigations:**

- Serum insulin: All samples will be assayed by immulite insulin. Principle of test: is a two-site chemiluminescent enzyme immunometric assay for use with the IMMULITE Automated Analyzer (Immulite DPC cirus).Results are expressed in (mic IU/mL).
- Blood glucose, blood urea, serum creatinine, serum cholesterol, serum triglyceride, serum high density lipoprotein and serum low density lipoprotein will be automated. RXL Analyzer from DADE Behring.

***Data Management:**

Data will be collected ,revised then edited on the personal computer.

Data will then be analyzeed statistically using SPSS statistical package version 13.

References:

-Villar J, Abalos E, Nardin JM, Merialdi M, Carroli G.

Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials. Semin Nephrol. 2004;24:607-615.

-Fisher SJ. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol. 2004; 2:53.

-Thadhani R, Ecker JL, Mutter WP, et al. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension. 2004;43:988-992.

-Enquobahrie DA, Williams MA, Butler CL, et al. Maternal plasma lipid concentrations in early pregnancy and risk of preeclampsia. *Am J Hypertens*. 2004;17:574-581.

-Raijmakers MT, Van Tits BJ, Hak-Lemmers HL, et al. Low plasma levels of oxidized low density lipoprotein in preeclampsia. *Acta Obstet Gynecol Scand*. 2004;83:1173-1177.

-Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O, et al. Evidence of a state of increased insulin resistance in preeclampsia. *American Journal of Hypertension* 1999;48:892-906.

-Caren G. Solomon ,Judith S. Carroll ,Kyoko Okamura, Steven W. Graves and Ellen W. Seely, et al. Higher cholesterol and insulin levels in pregnancy are associated with increased risk for pregnancy-induced hypertension. American Journal of Hypertension 1999;12:276-282.

دراسة نسبة الدهون وهرمون الأنسولين في السيدات
المصابات بمرض تسمم
الحمل والأخريات ذوات الحمل الطبيعي.

رسالة مقدمة من:

الطبيب/ أحمد صبحي محمد